This study tests a new oral medicine called Belumosudil, combined with corticosteroids, in people aged 12 and above who have just been diagnosed with chronic Graft Versus Host Disease (cGVHD). cGVHD is a condition where transplanted cells attack the body. Corticosteroids are medications that reduce swelling and inflammation.
The study includes:
- A screening process of up to 4 weeks.
- Treatment continues until the disease worsens, the patient experiences severe side effects, or chooses to stop.
- A minimum 30-day follow-up after the last dose.
To join, participants must be at least 12 years old, weigh over 40 kg, and have not received previous systemic treatment for cGVHD, except corticosteroids. They must not be pregnant or have certain medical conditions like uncontrolled infections or a history of certain viral infections.
Key points for participants:
- Study duration can be up to 5 years.
- Participants must be able to swallow tablets.
- Participants must provide informed consent.
How understandable was the trial content above?
Hard to understand
Easy to understand